Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 11/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.43 |
| ▸ | NR1H4 | Q96RI1 | 3/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2655940 | 0.88 | PLA2G2A (0.42) | PLA2G2AHDAC6HDAC1EPHX2NR1H4 | |
| SCHEMBL2644845 | 0.82 | CA1 (0.53) | HDAC6EPHX2NR1H4HDAC3HDAC8 | |
| Hydrochloric Acid SCHEMBL2644250 | 0.81 | CA1 (0.52) | HDAC6EPHX2NR1H4HDAC3HDAC8 | |
| SCHEMBL2652198 | 0.79 | LSS (0.38) | PLA2G2AHDAC6HDAC1EPHX2NR1H4 | |
| SCHEMBL2651344 | 0.77 | LSS (0.39) | PLA2G2AHDAC6HDAC1EPHX2NR1H4 | |
| SCHEMBL2655938 | 0.76 | HDAC1 (0.46) | PLA2G2AHDAC6HDAC1EPHX2NR1H4 | |
| SCHEMBL2651773 | 0.73 | EPHX2 (0.41) | HDAC6EPHX2NR1H4HDAC3HDAC8 | |
| SCHEMBL12373076 | 0.71 | HDAC6 (0.54) | HDAC6HDAC1EPHX2NR1H4HDAC3 | |
| SCHEMBL15896355 | 0.71 | ALDH1A1 (0.56) | PLA2G2A | |
| SCHEMBL26167954 | 0.69 | HDAC6 (0.56) | HDAC6HDAC1EPHX2NR1H4HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030203946-A1 | Glucagon antagonists/inverse agonists | NOVO NORDISK A/S (DK) | 2003-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030203946-A1 | Glucagon antagonists/inverse agonists | GLP1R, GPR119, GCGR | PLA2G2A 1428/4885HDAC6 3661/4885HDAC1 2196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.